Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Pharmiweb.com RSS Feed PharmiWeb Candidate Blog

Pharmiweb.com RSS Feed PharmiWeb Client Blog

Advertising

Features

1230 Features
Therapeutic & pharmaceutical opportunities for ost

28 Mar 03

In anticipation of the launch of Forteo, LeadDiscovery in collaboration with field-leader, Cees Vermeer have produced a state of the art report on both the field of osteoprosis in general and also mor
LeadDiscovery

PHARMIWEB SOAPBOX: Marketing Regulations – Is Onli

27 Mar 03

According to all pharmaceutical regulatory authorities of note, the regulations that apply to offline sales and marketing activity in the industry should also apply to all such activity in the online
Colin Williams

Schering-Plough: facing the challenges of blockbus

24 Mar 03

With the recent patent expiry of Claritin, a drug that netted Schering-Plough some $5 billion in sales in 2001-2002, the antihistamine market will soon be flooded by a raft of cheap generic copies of
Michael Randle

Natural bioactive compounds as therapeutic candida

20 Mar 03

Benign prostatic hypertrophy (BPH) is very common in men aged 50 years and older. Resultant bladder hyperactivity leads to self-enforced changes in life style, increased frequency of falls in the immo
LeadDiscovery

COX-II Inhibitors: Looking to drive market growth

20 Mar 03

With over $6 billion in sales in 2002, COX-II inhibitors are dominating the market for NSAIDs at a global level. These drugs have however, struggled to make an impact outside the US. With their long-t
Michael Randle

Rheumatoid Arthritis: Abbott looking for a greater

13 Mar 03

In rheumatoid arthritis treatment a shift towards the earlier use of DMARDs has threatened the dominance of the NSAID class of drugs. This has opened up considerable opportunity for drugs such as Remi
Michael Randle

Clinical Trials in Spain – An Update

13 Mar 03

Would you do a clinical study in Spain? The immediate reaction of the majority of the international clinical research community is “maybe but only at the later stages (Phase III-b, Phase IV)”. Spain i
Lewis Cameron

5-HT7 antagonists: Novel molecules for the unmet m

11 Mar 03

Due to the high incidence of migraine and its effect on quality of life the highly competitive triptan market exceeds of $2 billion in global sales. Triptans aborting a migraine attack once it has sta
LeadDiscovery

Retinoids : An A-Z guide to their biology, therape

28 Feb 03

Retinoids play a key role in differentiation, proliferation and apoptosis. As a result over 30 analogs of retinoic acid are now either in development or on the market. Retinoids in current use are eff
LeadDiscovery

Pfizer/Pharmacia: Moving the goalposts

26 Feb 03

The proposed merger between Pfizer and Pharmacia will create a company with total ethical sales twice those of its nearest competitor. Declining R&D productivity, and a flood of patent expirations hav
Michael Randle

Patients Wanted: Communication, Marketing and Tech

26 Feb 03

The process of finding, screening, and recruiting clinical trial patients at multiple research sites is a challenge for even the largest pharmaceutical sponsors and clinical research organizations.
Dr Faiz Kermani

eHealth News Roundup for 10th - 21st February, 200

26 Feb 03

The growing number of ePrescribing, health information and other technological initiatives mean that IT is becoming an ever more important and integral part of the healthcare system, for doctors and p
Michael Randle

Anticonvulsants: Pfizer's pregabalin to top succes

26 Feb 03

Ever since it first came to market in 1993, the anticonvulsant drug Neurontin has consistently been one of Pfizer's top earners, generating considerable sales and driving strong growth for the New Yor
Michael Randle

Drug Development: Time and Money

20 Feb 03

The pharmaceutical industry’s expectations for increasing revenue rely to a large extent on ensuring that their heavy R&D investment translates into new drugs. In 2000, the global pharmaceutical indu
Pietro Bonacossa

Multiple Myeloma: Increasing the therapeutic optio

20 Feb 03

High-dose therapy for multiple myeloma is effective in increasing median survival, but is severely toxic, limiting its use. In addition, all patients eventually relapse and suffer disease progression.
Michael Randle

Dinosaurs, Drugs and Politics

19 Feb 03

The pharmaceutical industry, much of which dreams of having the marketing agility of a primitive vertebrate, has found a sales-promotion tool that sometimes works in the United States and New Zealand.
Mark Chataway

Opportunities for the treatment of cancer, stroke

14 Feb 03

It is now well established that cellular suicide (apoptosis or programmed cell death) is central to a number of physiological cellular processes and is essential in the maintenance of homeostasis and
Dr Jon Goldhill

eHealth News Roundup for January 27th - February 7

11 Feb 03

The past fortnight saw a number of eHealth developments. Patients and consumer groups were particularly well catered for with the launch of important new cancer, diabetes, back pain, STD, substance ab
Michael Randle

Recruitment for Medical Jobs within the Pharmaceut

07 Feb 03

The pharmaceutical industry has a wide range of roles for medics, from clinical pharmacology where the clinical care of study subjects is your responsibility, to the position of medical adviser, which
Sue Ransom

Making a Success of R&D Partnerships

04 Feb 03

Biopharmaceutical companies face numerous challenges to boost their output of new chemical entities and to strengthen their product pipelines. In order to remain profitable and competitive, they have
Pietro Bonacossa

Driving Patient Compliance

03 Feb 03

Non-compliance is the failure of patients to take medicines in their prescribed manner. Patient non-compliance is a serious healthcare issue, with studies showing that it can range from 20% to 80% dep
Pietro Bonacossa

Hormonal Cancers: Key drivers in a market of chang

03 Feb 03

Four major brands, TAP’s Lupron, AstraZeneca’s Zoladex, Nolvadex and Casodex, account for 49% of the total value of the anti-hormonals market at present. The loss of patent protection for these compou
Michael Randle

eHealth News Roundup for 13th - 24th January 2003 from Datamonitor

03 Feb 03

Over the past fortnight the Internet has benefited from Healthcare initiatives with a number of online health information tools being launched in particular. Schering-Plough led the way on this front but the leading pharmaceuticals were not all so happy. GlaxoSmithKline, for example, recently received criticism over its threat to stop supplying drugs to Canadian online pharmacies. These stories and others are covered in detail in this week’s eHealth News Roundup.
Michael Randle

Lung Cancer: Eli Lilly’s Affinitac to challenge th

03 Feb 03

Lung cancer is one of the most prevalent forms of cancer to afflict both men and women, accounting for nearly 15% of all cancer cases. The size of the lung cancer market - estimated at $1.6bn in 2002
Michael Randle

TherapeuticAdvances: 23rd January 2003

03 Feb 03

The current edition of TherapeuticAdvances features data on the targeting of ion channels and TNF-alpha for treatment of inflammation; stem cell approaches to cardiovascular angiogenesis; improved pro
Dr Jon Goldhill

What’s your Drug Development Really Worth?

30 Jan 03

Drug development is an expensive and risk-intensive process. Even if a company manages to get its products to market, success is not guaranteed as there is the threat of competitors to contend with.
Dr Faiz Kermani

Diabetes: time for a new regime?

22 Jan 03

In 2001, diabetes drugs represented six of the leading 100 pharmaceutical brands in terms of global sales, combining for $8.2 billion in sales. Sales were led by Bristol-Myers Squibb's Glucophage fran
Michael Randle

Therapeutic Advances: 10th January 2003

15 Jan 03

The current edition of TherapeuticAdvances features data on anti-migraine drugs; emerging approaches to the blockade of transcription, angiogenesis and metastasis; and two therapeutic strategies for t
Dr Jon Goldhill

Advertising